Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases.
Paulína BelvončíkováMartin MarônekRoman GardlíkPublished in: International journal of molecular sciences (2022)
Gut microbiota dysbiosis has recently been reported in a number of clinical states, including neurological, psychiatric, cardiovascular, metabolic and autoimmune disorders. Yet, it is not completely understood how colonizing microorganisms are implicated in their pathophysiology and molecular pathways. There are a number of suggested mechanisms of how gut microbiota dysbiosis triggers or sustains extraintestinal diseases; however, none of these have been widely accepted as part of the disease pathogenesis. Recent studies have proposed that gut microbiota and its metabolites could play a pivotal role in the modulation of immune system responses and the development of autoimmunity in diseases such as rheumatoid arthritis, multiple sclerosis or type 1 diabetes. Fecal microbiota transplantation (FMT) is a valuable tool for uncovering the role of gut microbiota in the pathological processes. This review aims to summarize the current knowledge about gut microbiota dysbiosis and the potential of FMT in studying the pathogeneses and therapies of autoimmune diseases. Herein, we discuss the extraintestinal autoimmune pathologies with at least one published or ongoing FMT study in human or animal models.
Keyphrases
- multiple sclerosis
- type diabetes
- rheumatoid arthritis
- healthcare
- endothelial cells
- mental health
- ms ms
- cell therapy
- cardiovascular disease
- systematic review
- ankylosing spondylitis
- systemic lupus erythematosus
- systemic sclerosis
- skeletal muscle
- bone marrow
- metabolic syndrome
- weight loss
- white matter
- disease activity
- adipose tissue
- blood brain barrier
- climate change
- risk assessment
- subarachnoid hemorrhage
- case control